Viatris Gains China Approval for COPD Drug Yupelri, Triggers $7.5M Payment to Theravance BioPharma
Viatris Inc. (NASDAQ:VTRS) is one of the best low priced pharma stocks to buy now.
Theravance Biopharma Inc. (TBPH)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Madison Avenue Partners Eli Samaha | 9,511,150 | $84,934,570 | 7.21% | |
| 2. | Weiss Asset Management Andrew Weiss | 7,457,060 | $66,591,546 | 1.34% | |
| 3. | Newtyn Management Noah Levy And Eugene Dozortsev | 4,757,403 | $42,483,609 | 6.72% | |
| 4. | Irenic Capital Management Adam Katz And Andy Dodge | 2,760,948 | $24,655,266 | 3.74% | |
| 5. | Park West Asset Management Peter S. Park | 1,804,244 | $16,111,899 | +1% | 1.3% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $7.80 | 999,800 | $7,798,440.00 | 9,511,150 | 2024-08-07 | Filing | |
| $8.75 | 499,324 | $4,369,085.00 | 8,511,350 | 2024-05-01 | Filing | |
| $8.75 | 999,800 | $8,748,250.00 | 8,012,026 | 2024-05-01 | Filing | |
| $22.54 | 1,000 | $22,540.00 | 56,757 | 2018-05-21 | Filing | |
| $26.34 | 4,000 | $105,358.80 | 213,180 | 2017-08-21 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $11.39 | 4,000 | $45,551.60 | 326,918 | 2025-07-14 | Filing | |
| $11.39 | 5,318 | $60,548.09 | 330,918 | 2025-07-14 | Filing | |
| $11.39 | 682 | $7,769.82 | 336,236 | 2025-07-14 | Filing | |
| $11.00 | 24,000 | $264,000.00 | 336,918 | 2025-06-02 | Filing | |
| $9.00 | 4,000 | $36,000.00 | 370,038 | 2025-04-21 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 23,980 | $264,499 | 0% | |
| 2. | 14,315 | $157,894 | 0% | |
| 3. | 472 | $5,206 | 0% | |
| 4. | 425 | $4,688 | 0% | |
| 5. | 158 | $1,743 | 0% |
News See All
Theravance Biopharma, Inc. (NASDAQ:TBPH) Q1 2025 Earnings Call Transcript
Operator: Hello, ladies and gentlemen. Good afternoon. I would like to welcome everyone to the Theravance Biopharma First Quarter 2025 Conference Call.
Theravance Biopharma, Inc. (NASDAQ:TBPH) Q4 2024 Earnings Call Transcript
Theravance Biopharma, Inc. (NASDAQ:TBPH) Q4 2024 Earnings Call Transcript February 26, 2025Theravance Biopharma, Inc. misses on earnings expectations.
Theravance Biopharma, Inc. (NASDAQ:TBPH) Q3 2024 Earnings Call Transcript
Operator: Ladies and gentlemen, good afternoon. I would like to welcome everyone to the Theravance Biopharma Third Quarter 2024 Conference Call.
Theravance Biopharma, Inc. (NASDAQ:TBPH) Q2 2024 Earnings Call Transcript
Theravance Biopharma, Inc. (NASDAQ:TBPH) Q2 2024 Earnings Call Transcript August 5, 2024Theravance Biopharma, Inc. misses on earnings expectations.
Theravance Biopharma, Inc. (NASDAQ:TBPH) Q1 2024 Earnings Call Transcript
Operator: Ladies and gentlemen, good afternoon. I'd like to welcome everyone to the Theravance Biopharma First Quarter 2024 Conference Call.
Theravance Biopharma, Inc. (NASDAQ:TBPH) Q4 2023 Earnings Call Transcript
Theravance Biopharma, Inc. beats earnings expectations. Reported EPS is $0.03, expectations were $-0.04.
Billionaire Seth Klarman’s Biotech Stock Picks
In this article, we discuss billionaire Seth Klarman’s biotech stock picks.
Theravance Biopharma, Inc. (NASDAQ:TBPH) Q3 2023 Earnings Call Transcript
Operator: Ladies and gentlemen, good afternoon. I'd like to welcome everyone to Theravance Biopharma's Third Quarter 2023 Conference Call.
12 High Growth Value Stocks to Buy According to Seth Klarman
In this article, we will take a look at the 12 high growth value stocks to buy according to Seth Klarman.
Billionaire Hedge Funds
